TITLE

Chemoprevention of breast cancer

AUTHOR(S)
Levine, Mark; Moutquin, Jean-Marie; Walton, Ruth; Feightner, John
PUB. DATE
June 2001
SOURCE
CMAJ: Canadian Medical Association Journal;6/12/2001, Vol. 164 Issue 12, p1681
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Completion date: February 2001.
ACCESSION #
4620628

 

Related Articles

  • Novel polymorphisms in caspase-8 are associated with breast cancer risk in the California Teachers Study. Hannah Lui Park; Argyrios Ziogas; Jenny Chang; Bhumi Desai; Bessonova, Leona; Garner, Chad; Eunjung Lee; Neuhausen, Susan L.; Wang, Sophia S.; Huiyan Ma; Clague, Jessica; Reynolds, Peggy; Lacey Jr, James V.; Bernstein, Leslie; Anton-Culver, Hoda; Park, Hannah Lui; Ziogas, Argyrios; Chang, Jenny; Desai, Bhumi; Lee, Eunjung // BMC Cancer;1/12/2016, Vol. 16, p1 

    Background: The ability of tamoxifen and raloxifene to decrease breast cancer risk varies among different breast cancer subtypes. It is important to determine one's subtype-specific breast cancer risk when considering chemoprevention. A number of single nucleotide polymorphisms...

  • FRONTLINE.  // Women's Health Advisor;Jun2013, Vol. 17 Issue 6, p2 

    The article offers information on several studies related to the women's health. It includes a research related to the treatment of heart problems with cardiopoietic, stem cells, to improve symptoms in heart failure patients, a study related to identification of osteoporosis through computed...

  • OK'ing a Breast Cancer Drug. Hayden, Thomas // Newsweek (Atlantic Edition);11/09/98 (Atlantic Edition), Vol. 132 Issue 19, p48 

    Reports the United States Food and Drug Administration's (FDA) October 1998 approval of use of the drug tamoxifen to prevent breast cancer in women at high risk for the disease. Basis of the FDA decision on the results of a National Cancer Institute study; Those most likely to benefit; How...

  • OK'ing a Breast Cancer Drug. Hayden, Thomas // Newsweek;11/9/1998, Vol. 132 Issue 19, p63 

    Reports the United States Food and Drug Administration's (FDA) October 1998 approval of use of the drug tamoxifen to prevent breast cancer in women at high risk for the disease. Basis of the FDA decision on the results of a National Cancer Institute study; Those most likely to benefit; How...

  • OK'ing a Breast Cancer Drug. Hayden, Thomas // Newsweek (Pacific Edition);11/09/98 (Pacific Edition), Vol. 132 Issue 19, p50 

    Reports the United States Food and Drug Administration's (FDA) October 1998 approval of use of the drug tamoxifen to prevent breast cancer in women at high risk for the disease. Basis of the FDA decision on the results of a National Cancer Institute study; Those most likely to benefit; How...

  • CORRECTIONS.  // JAMA: Journal of the American Medical Association;9/5/2007, Vol. 298 Issue 9, p973 

    The article presents corrections to articles from previous issues including "Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial," published in the June 21, 2006 issue,...

  • Limited predictive value of achieving beneficial plasma (Z)-endoxifen threshold level by CYP2D6 genotyping in tamoxifen-treated Polish women with breast cancer. Hennig, Ewa E.; Piatkowska, Magdalena; Karczmarski, Jakub; Goryca, Krzysztof; Brewczynska, Elzbieta; Jazwiec, Radoslaw; Kluska, Anna; Omiotek, Robert; Paziewska, Agnieszka; Dadlez, Michal; Ostrowski, Jerzy // BMC Cancer;Aug2015, Vol. 15 Issue 1, p1 

    Background: Tamoxifen, the most frequently used drug for treating estrogen receptor-positive breast cancer, must be converted into active metabolites to exert its therapeutic efficacy, mainly through CYP2D6 enzymes. The objective of this study was to investigate the impact of CYP2D6...

  • The Italian Tamoxifen Prevention Trial. Bonanni, B.; Veronesi, U. // Disease Markers;1999, Vol. 15 Issue 1/3, p199 

    Presents a study which examined the effectiveness of the Italian tamoxifen prevention trial. Chemoprevention effect of tamoxifen against breast cancer; Breast cancer frequency of the placebo and tamoxifen arms; Methodology and results.

  • Treatment - Prevention.  // Current Medical Literature: Breast Cancer;2010, Vol. 22 Issue 1, p35 

    The article discusses the effectiveness and safety of tamoxifen, raloxifene and tribolone in decreasing the threat of primary breast cancer among women by sub-group through age, family record of breast cancer and menopausal condition. It states that the study contains double-blind,...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics